US equities |
SPCX $175.19 ▲+2.40% NVDA $242.30 ▲+1.42% MU $1,068.50 ▲+0.43% MRVL $291.52 ▲+7.47% AMD $651.22 ▲+3.08% SNDK $1,677.81 ▼-1.55% AVGO $376.55 ▲+3.87% TSLA $381.00 ▲+0.60%
FinancialContent

Latest News about Phase 2

Recent news which mentions Phase 2

Marker Therapeutics Secures $13.1M Grant To Support MultiTAA Cell Therapy Trial
Tickers MRKR
Tags Health Care Briefs Phase 2
From Benzinga
Paratek's Antibiotic Gets FDA Orphan Drug Tag For Lung Infection
Tickers PRTK
Tags Benzinga Orphan Drug Designation Biotech
From Benzinga
Galecto Starts Dosing In Mid-Stage Myelofibrosis Trial
Tickers GLTO
Tags myelofibrosis GLTO News
From Benzinga
DMC Recommends Biophytis Continue Sarconeos COVID-19 Study
Tickers BPTS
Tags News Phase 3 Trial Market News
From Benzinga